The myths and reality of empowerment.

T. Porter-O’Grady

1998-10-01

Nursing Management

Abstract:

What problem does this paper attempt to address?

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma

Ari A Kassardjian,Colton Ladbury,Borna Maraghechi,Chengyu Shi,Tyler Watkins,An Liu,Kevin Tsai,Terence Williams,Yun Rose Li,Savita Dandapani,Amanda Schwer,Percy Lee

DOI: https://doi.org/10.7759/cureus.67502

2024-08-22

Cureus

Abstract:In the context of oligometastatic renal cell carcinoma (RCC), local treatment with stereotactic body radiotherapy (SBRT) may improve oncologic outcomes. However, the location and size can often pose a technical challenge in standard SBRT delivery, and the dose is potentially limited by nearby organs at risk (OARs). Online adaptive radiotherapy (oART) improves radiation delivery by personalizing high-dose fractions to account for daily stochastic variations in patient anatomy or setup. The oART process aims to maximize tumor control and enhances precision by tailoring to a more accurate representation of a patient in near-real time. The proceeding re-optimization can mitigate the uncertainty inherent in the traditional radiation delivery workflow and precludes the need for larger margins that account for anatomical variations and setup errors. Here, we describe a case of oligometastatic RCC with a bulky (>300 cm3) pleural-based left lower lobe mass extending into the upper abdomen treated via personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR). Three fractions were delivered four weeks apart allowing for tumor shrinkage of these bulky lesions, and oART permitted on-table adaptation of the plan without traditional re-simulation and re-planning required during off-line adaptive radiotherapy. The plan was designed for the Ethos linear accelerator (Varian Medical Systems, Inc., Palo Alto, CA, USA). The prescription dose was 36 Gray (Gy) in three fractions, and the adapted plan was selected in each treatment over the scheduled plan due to better target coverage and reversal of OAR dose violations. The adapted plan met all OAR dose constraints, and it achieved higher target coverage in the first two PULSAR fractions compared to the scheduled plan. In the third fraction, the cumulative point dose was approaching the maximum heart tolerance, and target coverage was accordingly compromised based on clinical judgment. There was evidence of tumor regression throughout the course of treatment, and the patient did not develop any significant radiation-related toxicities. Follow-up imaging has demonstrated the overall stable size of her lesion without any evidence of disease progression. Our case reflects the benefit of adaptive SBRT delivery to a bulky mass near multiple OARs in the setting of oligometastatic RCC. The adapted plan allowed for prioritization of critical structures on a fraction-by-fraction basis while preserving the therapeutic intent of SBRT. Further integration of advanced imaging techniques, optimal disease-specific systemic immunotherapies or targeted therapies, and refinement of patient selection will be crucial in identifying which patients would most benefit from an adaptive approach.
Adapt-On-Demand: A Novel Strategy for Personalized Adaptive Radiation Therapy for Locally Advanced Lung Cancer

Ruiqi Li,Tingliang Zhuang,Steven Montalvo,Kai Wang,David Parsons,Yuanyuan Zhang,Puneeth Iyengar,Jing Wang,Andrew Godley,Bin Cai,Mu-Han Lin,Kenneth Westover

DOI: https://doi.org/10.1016/j.prro.2024.02.007

IF: 3.439

2024-05-06

Practical Radiation Oncology

Abstract:Purpose Real-time adaptation of thoracic radiation plans is compelling because offline adaptive experiences show that tumor volumes and lung anatomy can change during therapy. We present and analyze a novel adaptive-on-demand (AOD) workflow combining online adaptive radiation therapy (o-ART) on the ETHOS system with image guided radiation therapy delivery on a Halcyon unit for conventional fractionated radiation therapy of locally advanced lung cancer (LALC). Methods and Materials We analyzed 26 patients with LALC treated with the AOD workflow, adapting weekly. We timed segments of the workflow to evaluate efficiency in a real-world clinic. Target coverage and organ at risk (OAR) doses were compared between adaptive plans (ADP) and nonadaptive scheduled plans (SCH). Planning robustness was evaluated by the frequency of preplanning goals achieved in ADP plans, stratified by tumor volume change. Results The AOD workflow was achievable within 30 minutes for most radiation fractions. Over the course of therapy, we observed an average 26.6% ± 23.3% reduction in internal target volume (ITV). Despite these changes, with o-ART, ITV and planning target volume (PTV) coverage (V100%) was 99.2% and 93.9% for all members of the cohort, respectively. This represented a 2.9% and 6.8% improvement over nonadaptive plans ( P 10%, V100% was 93.1% for o-ART and 76.4% for nonadaptive plans, representing a median 17.2% improvement in the PTV coverage ( P < .05). In these plans, critical OAR constraints were met 94.1% of the time, whereas in nonadaptive plans, this figure was 81.9%. This represented reductions of 1.32 Gy, 1.34 Gy, or 1.75 Gy in the heart, esophagus, and lung, respectively. The effect was larger when tumors had shrunk more than 10%. Regardless of tumor volume alterations, the PTV/ITV coverage was achieved for all adaptive plans. Exceptional cases, where dose constraints were not met, were due to large initial tumor volumes or tumor growth. Conclusions The AOD workflow is efficient and robust in responding to anatomic changes in LALC patients, providing dosimetric advantages over standard therapy. Weekly adaptation was adequate to keep pace with changes. This approach is a feasible alternative to conventional offline replanning workflows for managing anatomy changes in LALC radiation therapy.

oncology,radiology, nuclear medicine & medical imaging
Single-Isocenter, Multiple-Target Abdominal Cone-Beam Computed Tomography (CBCT)-Guided Online Adaptive Stereotactic Body Radiotherapy (SBRT)

Chipo Raranje,Thomas R Mazur,Allen Mo,Eric Laugeman

DOI: https://doi.org/10.7759/cureus.68904

2024-09-07

Cureus

Abstract:Stereotactic body radiotherapy (SBRT) is increasingly being prescribed for treating patients with multiple metastases, especially in the setting of oligometastatic disease. Treating multiple targets presents unique challenges in radiotherapy planning and delivery, including practical considerations relating to treatment time, resource allocation, and treatment planning complexity. Treating targets in a common isocenter reduces the time required for treatment and simplifies planning, but historically, it has often not been feasible due to inter- and intra-fractional variation in relative target positions. With online adaptation, individual targets can be re-contoured on each treatment fraction to obviate inter-fractional variation, and with appropriate margin selection intra-fractional motion can be managed. In this case report, we describe single-isocenter, multiple-target treatment via online adaptation of a 93-year-old man with a history of metastatic hepatocellular carcinoma. He initially presented with a 9.1 cm liver mass, suspicious lung lesions, and an enlarged porta hepatis lymph node, which were biopsy proven to be hepatocellular carcinoma. Following 18 months of systemic immunotherapy, he demonstrated a favorable response, including a reduction in primary liver mass to 5.1 cm and resolution of pulmonary lesions; however, recent serial imaging demonstrated oligoprogression of two peripancreatic lymph node conglomerates that were biopsy proven to be poorly differentiated carcinoma. The patient was offered adaptive SBRT to a dose of 35-40 Gy in five fractions as a consolidative approach for treating both the primary liver mass and oligoprogressive lymph nodes. He tolerated treatment without any grade 2 or higher acute toxicity and had stable disease on three-month post-treatment imaging. By leveraging online adaptation, especially for the daily re-definition of target volumes, we were able to treat three targets in the abdomen accurately in a common isocenter. Treating in this manner vastly shortened and simplified the patient's radiation course. Quantitative evaluation of re-contoured targets and post-treatment imaging highlighted the value of online adaption with careful margin specification and alignment instructions.
Clinical Assessment of Autonomic Function

P. Thomson,K. Melmon

DOI: https://doi.org/10.1097/00000542-196807000-00019

IF: 8.986

1968-07-01

Anesthesiology

Abstract:
IVA-5 through-AIN implantation for a high transconductance self-aligned GaAs MESFET

H. Nishi,H. Onodera,H. Kawata,N. Yokoyama,A. Shibatomi

DOI: https://doi.org/10.1109/T-ED.1983.21377

IF: 3.1

1983-11-01

IEEE Transactions on Electron Devices

Abstract:
Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Non-Small Cell Lung Cancer Using Varian Ethos Therapy System

Vanda Leipold,Blanka Jakšić,Asmir Avdičević,Domagoj Kosmina,Hrvoje Kaučić,Ivana Alerić,Karla Schwarz,Mihaela Mlinarić,Giovanni Ursi,Adlan Čehobašić,Dragan Schwarz

DOI: https://doi.org/10.3390/curroncol31120562

2024-12-01

Current Oncology

Abstract:We present a patient treated with personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) for non-small cell lung cancer (NSCLC) using the adaptive Varian EthosTM system equipped with the novel HyperSight imaging platform. Three pulses of 12 Gy were separated by a pause of four weeks during which the tumor was given enough time to respond to treatment. Only initial planning computed tomography (CT) was acquired on a CT simulator (Siemens Somatom Definition Edge), whereas other pulses were adapted using online cone beam computed tomography (CBCT) images (iCBCT Acuros reconstruction) acquired while the patient was lying on the treatment couch and delivered immediately. Significant tumor reduction was achieved between pulses, resulting in improved organs-at-risk sparing. In addition, the on-couch plan optimization based on CBCT greatly reduced the patient's stay at the clinic and the duration of treatment preparation.

oncology
Beyond conventional bounds: Surpassing system limits for stereotactic ablative (SAbR) lung radiotherapy using CBCT‐based adaptive planning system

Yesenia Gonzalez,Justin Visak,Luke Overman,Chien‐Yi Liao,Allen Yen,Tingliang Zhuang,Bin Cai,Andrew Godley,Yuanyuan Zhang,Robert Timmerman,Puneeth Iyengar,Kenneth Westover,David Parsons,Mu‐Han Lin

DOI: https://doi.org/10.1002/acm2.14375

2024-05-09

Journal of Applied Clinical Medical Physics

Abstract:Purpose Online adaptive radiotherapy relies on a high degree of automation to enable rapid planning procedures. The Varian Ethos intelligent optimization engine (IOE) was originally designed for conventional treatments so it is crucial to provide clear guidance for lung SAbR plans. This study investigates using the Ethos IOE together with adaptive‐specific optimization tuning structures we designed and templated within Ethos to mitigate inter‐planner variability in meeting RTOG metrics for both online‐adaptive and offline SAbR plans. Methods We developed a planning strategy to automate the generation of tuning structures and optimization. This was validated by retrospective analysis of 35 lung SAbR cases (total 105 fractions) treated on Ethos. The effectiveness of our planning strategy was evaluated by comparing plan quality with‐and‐without auto‐generated tuning structures. Internal target volume (ITV) contour was compared between that drawn from CT simulation and from cone‐beam CT (CBCT) at time of treatment to verify CBCT image quality and treatment effectiveness. Planning strategy robustness for lung SAbR was quantified by frequency of plans meeting reference plan RTOG constraints. Results Our planning strategy creates a gradient within the ITV with maximum dose in the core and improves intermediate dose conformality on average by 2%. ITV size showed no significant difference between those contoured from CT simulation and first fraction, and also trended towards decreasing over course of treatment. Compared to non‐adaptive plans, adaptive plans better meet reference plan goals (37% vs. 100% PTV coverage compliance, for scheduled and adapted plans) while improving plan quality (improved GI (gradient index) by 3.8%, CI (conformity index) by 1.7%). Conclusion We developed a robust and readily shareable planning strategy for the treatment of adaptive lung SAbR on the Ethos system. We validated that automatic online plan re‐optimization along with the formulated adaptive tuning structures can ensure consistent plan quality. With the proposed planning strategy, highly ablative treatments are feasible on Ethos.

radiology, nuclear medicine & medical imaging
Adaptive-Driven CT Simulation-Free Soft Tissue Stereotactic Body Radiation Therapy: A Single-Patient Case Report

Malorie R Veres,Yasamin Sharifzadeh,James A Kavanaugh,Sean Park,Victor Malkov

DOI: https://doi.org/10.7759/cureus.66876

2024-08-14

Cureus

Abstract:Online adaptive radiotherapy (ART) enables accommodation for variations in patient setup and anatomical changes, allowing for fractional replanning for target coverage, organ at risk (OAR) sparing, and application of CT simulation-free (SF) workflows. SF workflows bypass the conventional simulation CT scan at the potential trade-off in dosimetric uncertainty. ART can alleviate many of these uncertainties, and this work extends previous experience with an Ethos adaptive cone-beam computed tomography (CBCT)-based SF process to treating a unique bony and soft tissue case with stereotactic body radiation therapy (SBRT). The patient is an 83-year-old male with metastatic prostate cancer, presenting with metastases near the right posterior ischium and a right perirectal lymph node. The patient's history includes multiple radiation treatments and androgen deprivation therapy (ADT). Rising prostate-specific antigen(PSA) levels and new metastases identified via positron emission tomography (PET)/CT prostate-specific membrane antigen (PSMA) led to SBRT re-irradiation, considered safe due to the time lapse since previous treatments. Using a HyperSight-equipped Ethos ART system, an SF SBRT workflow utilized the patient's recent PET/CT images for target and OAR delineation. A nine-field adaptive intensity-modulated radiotherapy(IMRT) treatment plan was generated to deliver 3600 Gy in three fractions with a primary focus to limit the dose to proximal OARs and the previously treated region. At the adaptive treatment, the patient is positioned based on anatomical marks, and axial images from HyperSight CBCT are used to contour the OARs and targets. These modified contours accommodate daily variations and are used to recalculate the reference plan and generate a new adapted plan. The adapted plan is selected if coverage improvement and OAR sparing are achieved. For each newly adapted plan, Ethos-generated synthetic CT is reviewed prior to treatment to verify no errors occurred in the deformable propagation between the reference image and the fractional CBCT. For this patient, the adapted plan was selected for all fractions due to improved target coverage, particularly of the soft tissue target, and OAR sparing. The patient tolerated the treatment well and demonstrated a good response on three-month follow-up PSMA PET/CT imaging. This case highlights the efficacy of CBCT-driven SF ART in complex re-irradiation scenario. Future enhancements in the Ethos treatment planning system, including direct dose computation on HyperSight CBCT images, will streamline SF workflows and expand their applicability. Careful consideration of potential on-unit OAR changes and target motion remains crucial for successful SF ART applications.
Technical feasibility of novel immunostimulatory low‐dose radiation for polymetastatic disease with CBCT‐based online adaptive and conventional approaches

Nour Nasser,Bradford A. Perez,Jose A. Penagaricano,Jimmy J. Caudell,Daniel E. Oliver,Kujtim Latifi,Eduardo G. Moros,Gage Redler

DOI: https://doi.org/10.1002/acm2.14303

2024-02-22

Journal of Applied Clinical Medical Physics

Abstract:Purpose A workflow/planning strategy delivering low‐dose radiation therapy (LDRT) (1 Gy) to all polymetastatic diseases using conventional planning/delivery (Raystation/Halcyon = "conventional") and the AI‐based Ethos online adaptive RT (oART) platform is developed/evaluated. Methods Using retrospective data for ten polymetastatic non‐small cell lung cancer patients (5‐52 lesions each) with PET/CTs, gross tumor volumes (GTVs) were delineated using PET standardized‐uptake‐value (SUV) thresholding. A 1 cm uniform expansion of GTVs to account for setup/contour uncertainty and organ motion‐generated planning target volumes (PTVs). Dose optimization/calculation used the diagnostic CT from PET/CT. Dosimetric objectives were: Dmin,0.03cc ≥ 95% (acceptable variation (Δ) ≥ 90%), V100% ≥ 95% (Δ ≥ 90%), and D0.03cc ≤ 120% (Δ ≤ 125%). Additionally, online adaptation was simulated. When available, subsequent diagnostic CT was used to represent on‐treatment CBCT. Otherwise, the CT from PET/CT used for initial planning was deformed to simulate clinically representative changes. Results All initial plans generated, both for Raystation and Ethos, achieved clinical goals within acceptable variation. For all patients, Dmin,0.03cc ≥ 95%, V100% ≥ 95%, and D0.03cc ≤ 120% goals were achieved for 84.8%/99.5%, 97.7%/98.7%, 97.4%/92.3%, in conventional/Ethos plans, respectively. The ratio of 50% isodose volume to PTV volume (R50%), maximum dose at 2 cm from PTV (D2cm), and the ratio of the 100% isodose volume to PTV volume (conformity index) in Raystation/Ethos plans were 7.9/5.9; 102.3%/88.44%; and 0.99/1.01, respectively. In Ethos, online adapted plans maintained PTV coverage whereas scheduled plans often resulted in geographic misses due to changes in tumor size, patient position, and body habitus. The average total duration of the oART workflow was 26:15 (min:sec) ranging from 6:43 to 57:30. The duration of each oART workflow step as a function of a number of targets showed a low correlation coefficient for influencer generation and editing (R2 = 0.04 and 0.02, respectively) and high correlation coefficient for target generation, target editing and plan generation (R2 = 0.68, 0.63 and 0.69, respectively). Conclusions This study demonstrates feasibility of conventional planning/treatment with Raystation/Halcyon and highlights efficiency gains when utilizing semi‐automated planning/online‐adaptive treatment with Ethos for immunostimulatory LDRT conformally delivered to all sites of polymetastatic disease.

radiology, nuclear medicine & medical imaging
Graph-Based Protein Functional Classification

Hyunjung Shin,A. M. Lisewski,O. Lichtarge

2007-07-01

Abstract:
The Charing Cross Hospital Child Development Centre: a description of its work ad an evaluation of its first 385 patients.

H. Jolly,N. Finnie,D. Hall,R. C. Newton,S. H. Roussounis

DOI: https://doi.org/10.1111/J.1365-2214.1977.TB00064.X

1977-11-01

Abstract:Charing Cross Hospital provides facilities for the study of handicapped children in a normal nursery which forms part of its Child Development Centre. The period of assessment varies from one day to three weeks; the advantages of prolonged assessment are discussed. Parental involvement and support, and the teaching of medical students are emphasized. A study of the Centre's first 385 patients is presented.
The First Reported Case of Treating the Ultra-Central Thorax With Cone Beam Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)

Stephanie Zhao,Robbie Beckert,Xiaodong Zhao,Eric Laugeman,Clifford G Robinson,Gregory Vlacich,Pamela P Samson,Joshua P Schiff

DOI: https://doi.org/10.7759/cureus.62906

2024-06-22

Cureus

Abstract:Stereotactic body radiotherapy (SBRT) to the central and ultra-central thorax is associated with infrequent but potentially serious adverse events. Adaptive SBRT, which provides more precise treatment planning and inter-fraction motion management, may allow the delivery of ablative doses to ultra-central tumors with effective local control and improved toxicity profiles. Herein, we describe the first reported case of cone beam computed tomography (CBCT)-guided stereotactic adaptive radiotherapy (CT-STAR) in the treatment of ultra-central non-small cell lung cancer (NSCLC) in a prospective clinical trial (NCT05785845). An 80-year-old man with radiographically diagnosed early-stage NSCLC presented for definitive management of an enlarging ultra-central lung nodule. He was prescribed 55 Gy in five fractions with CT-STAR. A simulation was performed using four-dimensional CT, and patients were planned for treatment at end-exhale breath-hold. Treatment plans were generated using a strict isotoxicity approach, which prioritized organ at risk (OAR) constraints over target coverage. During treatment, daily CBCTs were acquired and used to generate adapted contours and treatment plans based on the patient's anatomy-of-the-day, all while the patient was on the treatment table. The initial and adapted plans were compared using dose-volume histograms, and the superior plan was selected for treatment. The adapted plan was deemed superior and used for treatment in three out of five fractions. The adapted plan provided improved target coverage in two fractions and resolved an OAR hard constraint violation in one fraction. We report the successful treatment of a patient with ultra-central NSCLC utilizing CT-STAR. This case report builds on previously published in silico data to support the viability and dosimetric advantages of CT-STAR in the ablative treatment of this challenging tumor location. Further data are needed to confirm the toxicity and efficacy of this technique.
Cyclin E expression during development in Caenorhabditis elegans.

T. Brodigan,Ji Liu,Morgan Park,E. Kipreos,M. Krause

DOI: https://doi.org/10.1016/S0012-1606(02)00032-5

IF: 3.148

2003-02-01

Developmental Biology

Abstract:
Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?

Yinnan Meng,Wei Luo,Hailing Xu,Wei Wang,Suna Zhou,Xingni Tang,Zihong Li,Chao Zhou,Haihua Yang

DOI: https://doi.org/10.1016/j.radonc.2021.02.019

IF: 6.901

2021-05-01

Radiotherapy and Oncology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>Tumor and anatomical changes during radiotherapy have been observed in stage III non-small cell lung cancer (NSCLC) from many previous studies. We hypothesized that a routinely scheduled adaptive radiotherapy would have clinical important dose benefits to lower the risk of toxicities, without increasing the tumor recurrences.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We retrospectively reviewed 92 consecutive patients with inoperable stage III NSCLC between November 2017 and March 2019. All eligible patients received simultaneously integrated boost (SIB) using intensity-modulated radiation therapy (IMRT). A mid-treatment CT simulation and a new adapted plan were routinely given after the first 20 fractions. The organs at risk (OARs) were delineated per RTOG 1106 atlas. Dose-volume histograms were quantitatively compared between the initial and composite adaptive plans. Logistic regression was applied to analyze the dose-response relationship. Clinical endpoints included symptomatic acute symptomatic RP (RP2) and esophagitis (RE2), local controland regional tumor control, and progression-free survival (PFS).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Sixty-four eligible patients received adaptive SIB-IMRT were consecutively included. The GTVs reduced by a median of -38.2% after 42 to 44 Gy in 20 fractions of radiotherapy. By adapting to tumor and anatomical changes, dosimetric parameters of OARs decreased significantly. The mean lung dose decreased by an average of -74.8 cGy, and mean esophagus dose was lower by 183.1cGy. We found grade 2 or higher acute RP in 11 patients (17.2%), and RE2 in 28 patients (43.8%). Commonly used lung and esophagus dose metrics were significantly associated with RP2 and RE2. The adaptation could reduce RP2 probability by 3%, and RE2 risk by 5%. Subgroups with higher OARs dose or larger tumor shrinkage may get more dose and toxicities benefits. The estimated median PFS was 12.5 months from the start of radiotherapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>We demonstrated that the routinely adaptive SIB-IMRT strategy could significantly reduce the dose to surrounding normal tissues, potentially lower the associated acute RP and RE, without increasing the risk of tumor recurrences.</p>

oncology,radiology, nuclear medicine & medical imaging
Patient and Treatment Factors Associated with Improved Local Control and Survival in Oligometastatic Bone Disease: Results from a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy

Yu-Hui Chen,Elliot Fite,Andrew Pangilinan,Katerina Bubelo,Alexander Spektor,Mai Anh Huynh,Maria C. Thomas,Tracy A. Balboni

DOI: https://doi.org/10.1016/j.ijrobp.2022.06.096

2022-07-16

Abstract:Purpose Limited data exists to guide optimal patient selection and treatment of bone metastases with curative intent despite the increasing application of stereotactic body radiation therapy (SBRT) for oligometastatic (OM) disease control and re-irradiation(ReRT). Methods Clinical characteristics for 434 patients consecutively treated with bone SBRT at a single institution from 3/2011-6/2020 were analyzed by OM, spine, and non-spine bone using Cox regression to determine association with local control (LC), progression-free survival (PFS), and overall survival (OS), and the Kaplan-Meier method to estimate PFS and OS. Results Most patients had prostate (39%) or breast/lung (21%) cancer and 1-3 lesions (96%), with 651 lesions (spine 63%) treated for ReRT (12%) or OMD (88%), including synchronous (10%), metachronous (28%), repeat (27%), or induced (23%) states as defined by ESTRO/EORTC criteria. Biologically effective dose (BED 10 ) ≥50 (HR 0.68, CI 0.48-0.96, p<0.03) predicted improved LC among OM lesions and planning target volume (PTV)≥150 cc (HR 1.94, CI 1.02 to 3.70, p<0.04) predicted worse LC for non-spine bone. Prostate histology, performance status (PS) 0-1, and MFI ≥2 year predicted improved PFS and OS (p<0.05). Metachronous, synchronous, or repeat OM had higher PFS and OS (p≤0.001) than induced OM. With median follow-up 25.7 months, 1 and 2-year PFS was 63% and 47% for OM and 36% and 25% for ReRT;1 and 2-yr OS was 87% and 73% for OM, 58% and 43% for ReRT. Acute toxicities included grade 1-2 pain flare (9%) and fatigue (14%). Late toxicities included fracture (1%) for OM and myelopathy (2.5%) or nerve pain (1.2%) for ReRT. Conclusions BED 10 ≥ 50 for OM and PTV<150cc for non-spine bone lesions was associated with improved LC. Prostate histology, PS 0-1, MFI≥2 years, and metachronous, synchronous, or repeat presentations per EORTC/ESTRO OM criteria predicted improved PFS and OS among OM patients treated with bone SBRT.

oncology,radiology, nuclear medicine & medical imaging
Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases from Lung Adenocarcinoma

Kuan-Nien Chou,David J. Park,Yusuke S. Hori,Amit R. Persad,Cynthia Chuang,Sara C. Emrish,Louisa Ustrzynski,Armine Tayag,Kiran Kumar,Melissa Usoz,Maria Mendoza,Elham Rahimy,Erqi Pollom,Scott G. Soltys,Shiue-Wei Lai,Steven D. Chang

DOI: https://doi.org/10.1016/j.cllc.2024.05.007

IF: 4.84

2024-05-27

Clinical Lung Cancer

Abstract:Objective This study aimed to assess the results of primary stereotactic body radiotherapy (SBRT) for spinal bone metastases (SBM) originating from lung adenocarcinoma (ADC). We considered the revised Tokuhashi score (rTS), Spinal Instability Neoplastic Score (SINS), and genetic characteristics. Methods We examined adult patients with lung ADC who underwent primary SBRT (using the CyberKnife System) for SBM between March 2012 and January 2023. Results We analyzed data from 99 patients, covering 152 SBM across 194 vertebrae. The local control (LC) rate was 77.6% for SBM from lung ADC. The median period for local progression occurrence was recorded at 10.0 (3-52) months. Additionally, Asian patients demonstrated higher LC rates than White patients. Utilizing the rTS and SINS as predictive tools, we revealed that a poor survival prognosis and an unstable spinal structure were associated with increased rates of LP. Furthermore, the presence of osteolytic bone destructions and pain complaints were significantly correlated with the occurrence of LP. In the cohort of this study, 108 SBM underwent analysis to determine the expression levels of programmed cell death ligand 1 (PD-L1). Additionally, within this group, 60 showed mutations in the epidermal growth factor receptor (EGFR) alongside PD-L1 expression. Nevertheless, these genetic differences did not result in statistically significant differences in the LC rate. Conclusion The LC rate for primary SBRT targeting SBM from lung ADC stood at 77.6%, particularly with the use of the CyberKnife System. Patients achieving LC exhibited significantly longer survival times compared to those with LP.

oncology
Individualized Adaptive Radiotherapy Versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601

S. Yuan,Q. Yu,S. Wang,Y. Xu,H. Ge,J. Wang,S. Zhang,W. Chen,J. Li,Q. Song,W. Gu,J. Yan,X. Li,H. Zhang,D. Huang,B. Wang,C. Ai,L. Zhao,Y. Song,J. Yu

DOI: https://doi.org/10.1016/j.ijrobp.2020.07.2286

2020-01-01

Abstract:With the idea that proper dose-escalation radiotherapy would improve overall survival without increasing the probability of normal tissue complications, a trial was performed to compare overall survival after standard-dose versus individualized dose escalation based on FDG PET/CT and adaptive radiotherapy with chemotherapy for patients with inoperable stage III non-small-cell lung cancer(NSCLC). In this multicenter open-label randomized phase 3 trial in China, we enrolled patients (aged ≥18 years) with unresectable stage III NSCLC and randomly assigned (1:1) patients to receive either standard dose (60Gy/30fractions) or individualized adaptive dose escalation (≧66 Gy/30fractions) radiotherapy with concurrent and consolidation chemotherapy. In individualized group, the patients underwent CT and PET-based treatment planning at baseline and had CT resimulation and PET-CT in the original position after 18-20 fractions to tumor was delivered. A dose escalation ranged from 22-32Gy were delivered in 10 fractions in the second round to the adaptive target recontoured from the mid-treatment PET/CT with a regular normal tissue complication probability. Pemetrexed plus cisplatin was delivered for adenocarcinoma patients and docetaxel plus cisplatin was delivered for squamous cell carcinoma patients as concurrent and consolidation. The OS, PFS, ORR and adverse events were observed and assessed. From March 2014 to December 2018, 243 patients with inoperable stage III NSCLC were enrolled and 226 of them were included in statistical analysis who accomplished concurrent chemoradiotherapy, 2 cycles consolidation chemotherapy and at least 1 follow-up visit. than Compared to standard group, individualized group got significantly better OS (44.6 months vs 28.0 months, P = 0.001) and PFS (15.1 months vs. 11.6 months, P = 0.001) and similar objective response rates (73.33% vs. 65.29%, P = 0.192). Patients in both groups were well tolerated and no severe adverse events were significantly different. This randomized phase III multicenter trial demonstrated that individualized dose escalation to the adaptive target based on mid-treatment PET scans and IMRT achieved significantly better overall survival and progression free survival than standard 60Gy while got similar normal tissue complication probability in patients with locally advanced NSCLC.
CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experience

Albert Lee,Jared Pasetsky,Elizaveta Lavrova,Yi-Fang Wang,Geoffrey Sedor,Feng L Li,Matthew Gallitto,Matthew Garrett,Carl Elliston,Michael Price,Lisa A Kachnic,David P Horowitz

DOI: https://doi.org/10.1016/j.ctro.2024.100813

2024-07-07

Abstract:Purpose/objectives: Retrospective analysis suggests that dose escalation to a biologically effective dose of more than 70 Gy may improve overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but such treatments in practice are limited by proximity of organs at risk (OARs). We hypothesized that CT-guided online adaptive radiotherapy (OART) can account for interfraction movement of OARs and allow for safe delivery of ablative doses. Materials/methods: This is a single institution retrospective analysis of patients with PDAC treated with OART on the Ethos platform (Varian Medical Systems, a Siemens Healthineers Company, Palo Alto). All patients were treated to 40 Gy in 5 fractions. PTV overlapping with a 5 mm planning risk volume expansion on the stomach, duodenum and bowel received 25 Gy. Initial treatment plans were created conventionally. For each fraction, PTV and OAR volumes were recontoured with AI assistance after initial cone beam CT (CBCT). The adapted plan was calculated, underwent QA, and then compared to the scheduled plan. A second CBCT was obtained prior to delivery of the selected plan. Total treatment time (first CBCT to end of radiation delivery) and active physician time (first to second CBCT) were recorded. PTV_4000 V95 %, PTV_2500 V9 5%, and D0.03 cc to stomach, duodenum and bowel were reported for scheduled (S) and adapted (A) plans. CTCAEv5.0 toxicities were recorded. Statistical analysis was performed using a two-sided T test and α of 0.05. Results: 21 patients with unresectable or locally-recurrent PDAC were analyzed, with a total of 105 fractions. Average total time was 29 min and 16 s (16:36-49:40) and average active physician time was 19:41 min (9:25-39:34). All fractions were treated with adapted plans. 97 % of adapted plans met PTV_4000 V95.0 % >95.0 % coverage goal and 100 % of adapted plans met OAR dose constraints. Median follow up was 6.6 months. Only 1 patient experienced acute grade 3+ toxicity directly attributable to radiation. Only 1 patient experienced late grade 3+ toxicity directly attributable to radiation. Conclusions: Daily CT-based OART was associated with significantly reduced dose OARs while achieving superior PTV coverage. Given the relatively quick total treatment time, radiation delivery was generally well tolerated and easily incorporated into the clinic workflow. Our initial clinical experience demonstrates OART allows for safe dose escalation in the treatment of PDAC.
Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review

George J. Li,Hendrick Tan,Humza Nusrat,Joe Chang,Hanbo Chen,Ian Poon,Jeevin Shahi,May Tsao,Yee Ung,Patrick Cheung,Alexander V. Louie

DOI: https://doi.org/10.1016/j.ijrobp.2024.04.009

IF: 8.013

2024-05-13

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose We sought to evaluate the toxicity and efficacy of stereotactic body radiation therapy (SBRT) for ultracentral thoracic tumors at our institution. Methods and Materials Patients with ultracentral lung tumors or nodes, defined as having the planning target volume (PTV) overlapping or abutting the central bronchial tree and/or esophagus, treated at our institution with SBRT between 2009 and 2019 were retrospectively reviewed. All SBRT plans were generated with the goal of creating homogenous dose distributions. The primary endpoint was incidence of SBRT-related grade ≥3 toxicity, defined using the Common Terminology Criteria for Adverse Events (V5.0). Secondary endpoints included local failure (LF), progression-free survival (PFS), and overall survival. Competing risk analysis was used to estimate incidence and identify predictors of severe toxicity and LF, while the Kaplan-Meier method was used to estimate PFS and OS. Results A total of 154 patients receiving 162 ultracentral courses of SBRT were included. The most common prescription was 50 Gy in 5 fractions (42%), with doses ranging from 30 to 55 Gy in 5 fractions (BED10 range, 48-115 Gy). The incidence of severe toxicity was 9.4% at 3 years. The most common severe toxicity was pneumonitis (n = 4). There was 1 possible treatment-related death from pneumonitis/pneumonia. Predictors of severe toxicity included increased PTV size, decreased PTV V95%, lung V5 Gy, and lung V20 Gy. The incidence of LF was 14% at 3 years. Predictors of LF included younger age and greater volume of overlap between the PTV and esophagus. The median PFS was 8.8 months, while the median overall survival was 44.0 months. Conclusions In the largest case series of ultracentral thoracic SBRT to date, homogenously prescribed SBRT was associated with relatively low rates of severe toxicity and LF. Predictors of toxicity should be interpreted in the context of the heterogeneity in toxicities observed.

oncology,radiology, nuclear medicine & medical imaging
Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT)

Laura A Rechner,Mette Felter,Susanne Bekke,Susan Biancardo,Marianne F Rønjom,Mette Pedersen,David Sjöström,Inna M Chen,Patrik Sibolt

DOI: https://doi.org/10.7759/cureus.68386

2024-09-01

Cureus

Abstract:Pancreatic cancer is one of the most challenging tumor sites to treat safely and effectively with radiotherapy due to the anatomical location and aggressiveness of the disease. One modality that has shown promising results, which our institution has been employing, is online adaptive stereotactic radiotherapy using a magnetic resonance-guided linear accelerator (MR-linac). However, due to unforeseen circumstances regarding our MR-linac, it was necessary for our institution to use an alternative treatment technique. In this case report, we describe our experience using our ring-gantry linac equipped with an advanced cone-beam computed tomography (CBCT) system to treat a 61-year-old patient with advanced pancreatic cancer with CBCT-guided online adaptive stereotactic radiotherapy. In a short time period of four weeks, we prepared for this case by training with the surface scanning motion management system and developing procedures for planning and adaptation. The patient was prescribed 24 Gy in three fractions, with a risk-adapted approach using strict organ-at-risk (OAR) constraints. Daily CBCT was used for online adaptation of the plan, and the superior plan (non-adapted or adapted) was selected for treatment. For this patient, the adapted plan was chosen for all three fractions, due to OAR constraints being violated in the non-adapted plan. In summary, we found that for this patient, high-quality CBCT guidance for daily re-contouring, in combination with motion management, enabled the use of daily adaptive radiotherapy to safely deliver stereotactic radiotherapy. The results from this case report are promising, and CBCT-guided online adaptive stereotactic radiotherapy for pancreatic cancer warrants further investigation in more patients.

The myths and reality of empowerment.

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma

Adapt-On-Demand: A Novel Strategy for Personalized Adaptive Radiation Therapy for Locally Advanced Lung Cancer

Single-Isocenter, Multiple-Target Abdominal Cone-Beam Computed Tomography (CBCT)-Guided Online Adaptive Stereotactic Body Radiotherapy (SBRT)

Clinical Assessment of Autonomic Function

IVA-5 through-AIN implantation for a high transconductance self-aligned GaAs MESFET

Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Non-Small Cell Lung Cancer Using Varian Ethos Therapy System

Beyond conventional bounds: Surpassing system limits for stereotactic ablative (SAbR) lung radiotherapy using CBCT‐based adaptive planning system

Adaptive-Driven CT Simulation-Free Soft Tissue Stereotactic Body Radiation Therapy: A Single-Patient Case Report

Technical feasibility of novel immunostimulatory low‐dose radiation for polymetastatic disease with CBCT‐based online adaptive and conventional approaches

Graph-Based Protein Functional Classification

The Charing Cross Hospital Child Development Centre: a description of its work ad an evaluation of its first 385 patients.

The First Reported Case of Treating the Ultra-Central Thorax With Cone Beam Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)

Cyclin E expression during development in Caenorhabditis elegans.

Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?

Patient and Treatment Factors Associated with Improved Local Control and Survival in Oligometastatic Bone Disease: Results from a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy

Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases from Lung Adenocarcinoma

Individualized Adaptive Radiotherapy Versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601

CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experience

Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review

Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT)